Stereotaxis to Present at Upcoming Investor Conferences
Stereotaxis (NYSE: STXS) announced that Chairman and CEO David Fischel will present at two investor conferences in Q1 2021. He will provide an overview of the company's business at the BTIG Virtual MedTech Conference on February 17, 2021, at 1:00 PM EST, and the Cowen Virtual 41st Annual Health Care Conference on March 1, 2021, at 11:00 AM EST. Fischel expressed gratitude for the invitations and aims to share Stereotaxis’ innovative technologies and growth strategies. One-on-one meetings can be arranged for interested investors.
- None.
- None.
ST. LOUIS, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in the first quarter 2021.
- BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Mr. Fischel will present an overview of Stereotaxis business on Wednesday, February 17th, 2021, at 1:00 pm EST and will be available that day for one-on-one meetings.
- Cowen Virtual 41st Annual Health Care Conference
Mr. Fischel will present an overview of Stereotaxis business on Monday, March 1, 2021, at 11:00 am EST, and will be available that day for one-on-one meetings.
“We appreciate the invitations to these conferences and look forward to sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with the investment community,” says Mr. Fischel. One-on-one meetings with Mr. Fischel can be arranged through registration with these conferences.
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
FAQ
When will David Fischel present at the BTIG Virtual MedTech Conference?
What is the date of the Cowen Virtual 41st Annual Health Care Conference?
What is the focus of Stereotaxis' presentations at the investor conferences?
How can investors arrange one-on-one meetings with David Fischel?
What stock symbol is associated with Stereotaxis?
